Pharma
Commented by André Will-Laudien on May 21st, 2026 | 07:10 CEST
Undervalued – Analysts Turn Their Attention to Life Sciences: Bayer, Vidac Pharma, Novo Nordisk, and Pfizer in Focus
DZ Bank's aggressive price target adjustment for Bayer demonstrates that analysts have recently begun to view the life sciences sector more favourably. The pharmaceutical and agrochemical group's strong start to the year has led to significantly improved prospects, and legal risks are now also viewed as more moderate. Finally, some good news for long-suffering investors in a geopolitically volatile environment. After all, there have not been any major upgrades in the sector for quite some time. When it comes to Novo Nordisk, however, experts remain divided on whether the earnings trend will turn positive again. Cutthroat competition in the weight-loss drug market is intense, putting pressure on margins. Buoyed by industry sentiment, Pfizer also saw its stock rise again. Time for a new tour of the sector. Where are the triggers?
Read
Commented by Nico Popp on May 14th, 2026 | 07:50 CEST
Checkmate for Cancer: What Eli Lilly and Bayer Can Learn from Vidac Pharma
Modern medicine is on the cusp of groundbreaking innovations in which the regulation of cellular energy metabolism, known as metabolic correction, is becoming a decisive strategy. While traditional cancer research has relied primarily on the destruction of cells using toxic agents for decades, researchers now recognize that the key to success may lie in the precise control of enzymatic processes. In light of this, value creation is shifting away from the conventional "sledgehammer approach" toward correcting cellular dysregulation. We highlight three exciting companies and focus in particular on metabolism pioneer Vidac Pharma.
Read
Commented by Mario Hose on May 8th, 2026 | 07:00 CEST
Yield Hunters Take Note! TUI and Novo Nordisk Signal a Rebound – Zefiro Methane Launches the Methane Revolution
May 2026 is shaping up to be an exciting month for strategic investors and yield hunters. While the major players, TUI and Novo Nordisk, are already beginning to stage a strong rebound following a period of consolidation, a new dynamic is quietly emerging that could influence share prices going forward. Demand for travel remains robust, while the Danish pharma giant's market dominance has been reinforced by seemingly strong quarterly results, making both stocks attractive candidates for a recovery rally. While established companies provide a degree of "stability," a specialized environmental services provider aims to disrupt the sustainability market. Zefiro Methane may be on the verge of a major operational breakthrough and is also approaching a key technical price level. Investors who correctly interpret the signals of expansion and technical strength may recognize a rare combination of solid fundamentals and explosive potential. It is time to take a closer look at the companies currently driving the market.
Read
Commented by Fabian Lorenz on April 30th, 2026 | 07:40 CEST
Buy recommendations for Rheinmetall and Antimony Resources! What is going on at Bayer?
Created and published on behalf of Antimony Resources Corp.
Is Rheinmetall's stock heading back toward EUR 2,000? Maybe even higher? Analysts are convinced of this. Negative scenarios are already priced into the share price. The latest order shows that operations are running smoothly at Germany's largest defence contractor. Strong news from Antimony Resources as well. Drilling results are impressive once again, making analysts' price targets increasingly plausible. They see the stock rising by over 150%. Bayer shares have had a tough time in recent weeks. The glyphosate stress is back. The issue had been sidelined for months, and the stock had been on an upward trajectory. Then, starting in mid-February, came the sharp sell-off. What do analysts say?
Read
Commented by Armin Schulz on April 30th, 2026 | 07:00 CEST
Weight-Loss Injections, Cancer Cell Inhibitors & the Power of Algorithms: Adding Potential to Your Portfolio with Novo Nordisk, Vidac Pharma, and Evotec
The healthcare market faces a paradoxical scenario in 2026. Public health funds are groaning under record spending, while groundbreaking technologies are redefining medicine. AI-driven drug discovery and personalized therapies promise efficiency gains, but regulatory hurdles and price wars are causing stock prices to fluctuate. In this complex landscape, the wheat is being separated from the chaff. Three distinct biotech strategies could now provide the decisive edge. Novo Nordisk dominates the mass market for metabolic diseases, Vidac Pharma is tackling cancer in novel ways, and Evotec is digitizing the entire drug discovery process.
Read
Commented by Fabian Lorenz on April 20th, 2026 | 08:10 CEST
Insider Sales, Buy Ratings, and AI Momentum: BioNTech, Evotec, and Vidac Pharma in Focus
Insider sales at Vidac Pharma. However, this is not necessarily a cause for concern and may rather present a potential entry opportunity. The company is working on a revolutionary cancer therapy, with key milestones expected in 2026. Analysts see significant upside potential, and there is also speculation about a possible takeover. AI-driven expectations are giving Evotec shares new momentum. Analysts recommend buying the stock, although there are also reasons for caution. At BioNTech, the market appears to have absorbed the impact of the founders' departure. Following positive study data, analysts see further upside potential.
Read
Commented by Mario Hose on April 13th, 2026 | 07:30 CEST
100% Profit Potential in Sight: Vidac Pharma's Chance to Double vs Bayer and Evotec
Even in the spring of 2026, the stock market remains highly volatile. The upheavals caused by geopolitical crises have been and remain significant and ever-present. While heavyweights like Bayer are struggling to shake off their legal baggage and Evotec is steering into calmer waters, a stock from the back row is suddenly stepping into the spotlight. Vidac Pharma has also had a few turbulent months, and this is precisely where experienced investors now sense an opportunity. With a current share price of EUR 0.56, the company is poised for a potential recovery, an uptick, and perhaps even a complete revaluation. If the strategy pays off, the EUR 1 mark could be reached. That would be a chance to double their money for bold investors. But what is behind this optimism? In this report, we take a look at the industry giants and analyze not only them but also why, of all three, the one with the smallest market capitalization could develop the greatest momentum. It is about potential breakthroughs in cancer research and a management team that is optimizing many aspects for success.
Read
Commented by Carsten Mainitz on April 10th, 2026 | 08:20 CEST
Unlocking Massive Potential in Pharma's Largest Segment: Innovator Vidac Pharma, Industry Leader Bayer, or Turnaround Candidate Evotec?
Oncology is the most strategically important growth market in the pharmaceutical industry and at the same time one of the key levers for improving global health. Currently, around 20 million people worldwide are diagnosed with cancer each year, a figure expected to exceed 30 million annually by 2040. The global oncology drug market is already valued at over USD 200 billion and continues to expand rapidly. Bayer aims to rank among the world's leading oncology players by 2030 and recently reaffirmed its medium-term targets. Following the sale of a stake in a cancer specialist, shareholders of Evotec, which has faced significant pressure, may soon benefit from a welcome inflow of funds. Vidac Pharma, on the other hand, is breaking new ground in the fight against skin cancer. There is enormous potential here.
Read
Commented by Nico Popp on March 31st, 2026 | 08:20 CEST
Dividends as Portfolio Anchors: Familiar Names Sanofi and BB Biotech – Hidden Gem RE Royalties
In a market environment marked by structural upheaval, portfolio stability is increasingly coming into focus. Analysts at JPMorgan emphasize that preserving accumulated gains requires a renewed focus on resilience and diversification. Research by S&P Global also shows that dividends have contributed over 50% to the total return of global equities over the past 25 years. Choosing the right stocks is crucial to securing steady cash flows even during volatile market phases. Pharmaceutical giant Sanofi, investment firm BB Biotech, and the virtually unknown Canadian company RE Royalties offer fundamentally different but extremely promising approaches for investors.
Read
Commented by Nico Popp on March 30th, 2026 | 08:30 CEST
A Paradigm Shift in Oncology: Core Stocks Roche & Galderma and the High-Leverage Opportunity in Vidac Pharma
Medical advances affect us all. Oncology is also undergoing a transformation. As conventional immunotherapies for skin cancer increasingly reach their limits, clinical research is shifting its focus to correcting defective tumor metabolism. The Warburg effect, where cancer cells shift energy production to aerobic glycolysis to fuel uncontrolled growth, offers a promising entry point. This dynamic development landscape is exacerbated by an impending patent cliff, which, according to calculations by the consulting firm PwC, threatens industry revenues of USD 104 billion by 2028, as many patents for active ingredients are expiring. Currently, market researchers at Fortune Business Insights estimate the volume of the global oncology market for 2026 at USD 286.36 billion. While pharmaceutical giant Roche secures its market leadership and the Galderma Group dominates standard dermatological care, biotechnology company Vidac Pharma is targeting the metabolic vulnerability of cancer cells with a completely novel mechanism of action, aiming to effectively shut down the cancer.
Read